| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | XE:BAYN | XETRA | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.25 | 0.48% | 52.37 | 52.28 | 52.39 | 52.39 | 51.85 | 52.00 | 1,234,042 | 16:35:13 |
Bayer Raises Combined Peak Sales Forecast for Pharma Portfolio
10/01/2023 2:06pm
Dow Jones News
Bayer (XE:BAYN)
Historical Stock Chart
From Dec 2022 to Jun 2023
By Giulia Petroni
Bayer AG on Tuesday raised its peak sales forecast for its pharma portfolio to more than 12 billion euros ($12.8 billion) amid potential blockbuster drugs tracking ahead of schedule and targeted investments.
The German pharmaceutical company said that drugs Nubeqa and Kerendia have registered a strong market uptake and could generate sales of more than EUR3 billion each. Nubeqa is used for the treatment of prostate cancer patients while Kerendia targets cardio-renal disease.
Asundexian, which could potentially serve as a distinct option for the prevention of thrombosis and ischemic strokes, has projected peak sales of more than EUR5 billion, according to Bayer.
"New therapeutic targets and modalities are increasingly contributing to our early development portfolio and already representing a large part of our annual R&D resources, reflecting their importance for our renewed strategy," Christian Rommel, head of research and development, said. "For 2023, we are expecting several important development milestones for both our early and late-stage pipeline that will allow us to further advance medical innovations."
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
January 10, 2023 08:51 ET (13:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |